Orasi Medical Inc., the University of Minnesota spin-off developing software to speed drug trials, is close to signing a deal to license its technology to one or more major pharmaceutical companies. CEO Shawn Lyndon told MedCity News he expects to announce a deal in a month or so. Though Lyndon declined to specifically name companies, […]
The Minnesota company's primary market is to diagnosis the advance of Alzheimers, but the company says the process can also measure the effect of neurological treatments. This second round of funding will expand the development and use of the test to see how well compounds to treat neurological diseases.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.